Empagliflozin and Functional Aerobic Capacity in Individuals with Increased Risk of Heart Failure: The Empire Prevent Cardiac Trial

Key Result

Empagliflozin did not improve VO2 max, physical activity level, or quality of life in elderly individuals at risk of heart failure.

Key Points

• To evaluate the effects of empagliflozin on aerobic capacity and quality of life in elderly individuals at risk for heart failure.
• Randomized trial design
• Population included elderly individuals with overweight or obesity
• Measured outcomes included VO2 max, physical activity level, and quality of life
• Statistical analysis of differences pre- and post-intervention
• Empagliflozin did not significantly change VO2 max levels
• No effect on physical activity levels was observed
• Quality of life remained unchanged among participants